Search Results - "Selej, M."

OPUS Registry: Safety and Tolerability of Macitentan in a Real-World Setting by Kim, N.H, Brand, M, Chin, K.M, Channick, R.N, Selej, M, McLaughlin, V.V

Get full text

Updated Risk Score Calculator for Pulmonary Arterial Hypertension Patients by Benza, R.L, Elliott, C.G, Farber, H.W, Foreman, A.J, Frost, A.E, Gomberg-Maitland, M, McGoon, M.D, Pasta, D.J, Selej, M, Frantz, R.P

Get full text

(213) - Diagnostic Accuracy of Automatic Tricuspid Regurgitation Jet Velocity for Detecting Pulmonary Hypertension by Salehi, M., Alabed, S., Sharkey, M., Maiter, A., Dwivedi, K., Yardibi, T., Selej, M., Hameed, A., Charalampopoulos, A., Kiely, D., Swift, A.J.

Get full text

(858) - A Transthoracic Echocardiography (TTE) Based PH Detection Model Using View Agnostic Classifier by Damasceno, P., Fadnavis, S., Emaminejad, N., Ulloa Cerna, A., Parmar, C., Standish, K., Mansi, T., Dunnmon, P., Yardibi, T., Selej, M.

Get full text

Patient Characteristics and Treatment Patterns with Macitentan in Pulmonary Arterial Hypertension: Insights from the OPUS Registry by Channick, R., Chin, K., Kim, N., Brand, M., Morganti, A., Selej, M., McLaughlin, V.

“…To describe the real-world use and safety profile of macitentan in patients with pulmonary arterial hypertension (PAH) enrolled in the OPsumit® USers registry…”
Get full text

P3560Real-world experience with concomitant macitentan and riociguat treatment in patients with pulmonary hypertension (PH) in the OPsumit USers (OPUS) registry by McLaughlin, V, Chin, K, Kim, N, Sulica, R, Frantz, R, Brand, M, Muros-Le Rouzic, E, Selej, M, Channick, R

Get full text

(367) - OPUS Registry: Switching to Macitentan From Other Endothelin Receptor Antagonists (ERAs) by Ravichandran, A., Channick, R., Chin, K.M., Kim, N.H., Brand, M., Selej, M., McLaughlin, V.V.

Get full text

Treatment of Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Real-World Experience with Macitentan by Channick, R., McLaughlin, V., Chin, K., McConnell, J., Poch, D., Brand, M., Selej, M., Morganti, A., Kim, N.

“…To describe real-world experience with macitentan in patients with CTEPH enrolled in the OPsumit® USers registry (OPUS; NCT02126943). OPUS is an ongoing,…”
Get full text

A68 WOW: PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION: Opus Registry: Treatment Patterns With Macitentan In Patients With Pulmonary Arterial Hypertension by Chin, K, Channick, R N, Kim, N H, Rouzic, E Muros-Le, Selej, M, McLaughlin, V

“…Corresponding author's email: kelly.chin@utsouthwestem.edu Rationale:The OPsumit USers registry (OPUS; NCT02126943) characterizes the use and safety profile of…”
Get full text

First Results of Soprano: Macitentan in Patients (pts) with Pulmonary Hypertension (PH) Post-Left Ventricular Assist Device (LVAD) Implantation by Frantz, R.P., Desai, S., Ewald, G., Franco, V., Hage, A., Horn, E.M., LaRue, S.J., Mathier, M.A., Mandras, S.A., Park, M.H., Ravichandran, A., Wang, I., Zolty, R., Rocco, M., Selej, M., Zhao, C., Rame, J.

“…To assess the efficacy and safety of macitentan in pts with PH post-LVAD. SOPRANO (NCT02554903) was a double-blind, randomized, study of macitentan 10 mg…”
Get full text

PCV2 - Characterizing Patients Treated With Macitentan For Pulmonary Arterial Hypertension (PAH) In The U.S. Opsumit Users Registry (OPUS) by McLaughlin, VV, Channick, RM, Lickert, C, Pruett, J, Selej, M, Drake, W

Get full text

Characterizing Patients Treated With Macitentan For Pulmonary Arterial Hypertension (PAH) In The U.S. Opsumit Users Registry (OPUS) by McLaughlin, VV, Channick, RM, Lickert, C, Pruett, J, Selej, M, Drake, W

Get full text

D54 CLINICAL PULMONARY HYPERTENSION: Opsumit® Users Registry (opus): Insights Into The Safety And Tolerability Of Opsumit by Kim, N H, Chin, K M, Rouzic, E Muros-Le, Brand, M, Selej, M, Channick, R N, McLaughlin, V V

Get full text

C106 MONEY DON'T MATTER TONIGHT: PULMONARY HYPERTENSION ASSESSMENT, PROGNOSTICATION, AND TREATMENT: Updated Risk Score Calculator For Patients With Pulmonary Arterial Hypertension (pah) In The Registry To Evaluate Early And Long-Term Pah Disease Management (reveal) by Benza, R L, Elliott, C, Farber, H, eman, A J, Frost, A E, Gomberg-Maitland, M, McGoon, M D, Pasta, D J, Selej, M, Frantz, R P

“…Risk score variables with new cut-points included brain natriuretic peptide (BNP), portopulmonary hypertension, heart rate, percent predicted diffusing…”
Get full text

B19 LATE BREAKING ABSTRACTS IN DISEASE ASSESSMENT AND CHARACTERIZATION: Novel Risk Score Prediction Using Inflammatory Cytokines In Pulmonary Arterial Hypertension by Selej, M, Tian, L, Scalfone, L, Lawrie, A, Nicolls, M R, Robinson, W, Rabinovitch, M, Zamanian, R T

Get full text

C106 WRECKING BALL: NEW PARADIGMS IN UNDERSTANDING AND TREATMENT OF PH: Predicting Outcomes In Pulmonary Arterial Hypertension Based On Estimated Glomerular Filtration Rate by Chakinala, M M, Coyne, D W, Benza, R L, Frost, A E, McGoon, M D, Hartline, B K, Frantz, R P, Selej, M, Mink, D R, Farber, H W

Get full text

ALCAPA: A Rare Cause of Cardiac Arrest by Selej, Mona, MD

Get full text

Load Adaptability in Patients with Pulmonary Arterial Hypertension by Amsallem, Myriam, MD MS, Boulate, David, MD MS, Aymami, Marie, MD MS, Guihaire, Julien, MD PhD, Selej, Mona, MD MS, Huo, Jennie, MD, Denault, Andre Y., MD PhD, McConnell, Michael V., MD MSEE, Schnittger, Ingela, MD, Fadel, Elie, MD PhD, Mercier, Olaf, MD PhD, Zamanian, Roham T., MD PhD, Haddad, Francois, MD

“…Abstract Right ventricular (RV) adaptation to pressure overload is a major prognostic factor in patients with pulmonary arterial hypertension (PAH). The…”
Get full text

Sarcoidosis: A Great Imitator by Selej, Mona, MD, Bosslet, Gabriel, MD

Get full text

Noncardiogenic Pulmonary Edema in Amlodipine Overdose by Selej, Mona, MD, Farber, Mark, MD

Get full text